Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes

Abstract

IntroductionHypoglycemia is the most common adverse effect of diabetes therapy, particularly insulin treatment. Hypoglycemia is associated with considerable clinical and economic burden, and may be under-reported. The aim of this study was to com pare the frequency of hypoglycemic events reported in real-world settings with those reported in clinical trials.MethodsWe conducted a structured literature review in PubMed to identify hypoglycemic event rates in patients with type 1 diabetes mellitus (T1DM) and insulin-treated type 2 diabetes mellitus (T2DM) from real-world data (RWD) and randomized controlled trials (RCTs). The search was restricted to English language, full-text publications from 2010 onwards, reporting on treatment of T1DM or T2DM with basal only, basal-bolus, or premix insulin.ResultsThe final dataset included 30 studies (11 RWD studies and 19 RCTs). Six studies (RWD, n = 2; RCT, n = 4) reported hypoglycemia event rates in people with T1DM. For all reported categories of hypoglycemia (severe, non-severe, and nocturnal), rates were consistently higher in RWD studies compared with RCTs. Twenty-five studies (RWD, n = 10; RCT, n = 15) reported hypoglycemia event rates in people with insulin-treated T2DM. For T2DM basal-oral therapy; the highest rates were observed in RWD studies, although there was an overlap with RCT rates. For basal-bolus therapy, there was considerable between-study variability but higher rates of severe and non-severe hypoglycemia were generally observed in RWD studies. For T2DM premix insulin, reported rates of hypoglycemia in RWD studies and RCTs were similar.ConclusionWe found that higher rates of hypoglycemia are observed in real-world settings compared with clinical trial settings, although there is a large degree of overlap. Due to the inherent constraints of RCTs, they are likely to underestimate the burden of hypoglycemia in clinical practice. Further, high-quality RWD are needed to determine a more accurate incidence of hypoglycemia in clinical practice.Electronic supplementary materialThe online version of this article (doi:10.1007/s13300-016-0157-z) contains supplementary material, which is available to authorized users.

Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial

“…This may have led to misclassification and/or overestimation of hypoglycemic events. Fourth, rates of hypoglycemia observed in randomized clinical trials may be lower than those obtained from real world data (35). Although not a formal exclusion criteria in our trial, physicians may have chosen to exclude patients with recurrent hypoglycemic events or hypoglycemia unawareness, thus resulting in lower hypoglycemia rates compared with the "real world" population with diabetes.…”

Real-world cardiovascular disease burden in patients with atherosclerotic cardiovascular disease: a comprehensive systematic literature review

“…We compared the MACE rates observed in real-world studies with those reported in a recent comprehensive meta-analysis of 26 clinical trials 15 . According to the CTTC, The importance of considering RWE has been discussed in prior studies 12,[32][33][34] . Although RCTs are considered the "gold standard" for establishing the efficacy of specific interventions, this methodological approach is probably not sufficient for describing the epidemiology and real-world disease burden in the general population.…”

“…This is demonstrated by the stringent patient selection criteria (e.g. exclusion of high risk patients) and highly controlled clinical settings typically employed by RCTs, leading to limited generalizability of disease burden to the general population and routine clinical practices 12,[32][33][34] . Elliot et al 12 found that rates of hypoglycemia were consistently higher in real-world studies compared to RCTs in patients with type 1 or type 2 diabetes.…”

“…Although the general improvement in CVD mortality rates has been documented, the real-world burden of secondary CVD events in patients with elevated LDL-C is unclear. It is especially important to examine real-world evidence (RWE) as clinical trials of other conditions typically report lower incident rates 12 . In order to understand the current burden of CVD worldwide in people with prior major adverse cardiovascular events (MACEs) and elevated LDL-C, we conducted a systematic literature review of real-world global literature on the topic.…”

Economic evaluation of type 2 diabetes mellitus burden and its main cardiovascular complications in the Russian Federation

“…При всех известных ограничениях исследований реальной практики назначений, связанных как с осо-бенностями системы обеспечения лекарственными пре-паратами, так и с различными подходами к практике ведения больных у различных специалистов, такие дан-ные считаются важным дополнением к официальной статистике и позволяют сфокусироваться на нерешенных проблемах медицинской помощи [11,12]. Данные ана-лиза врачебной практики в нашей стране показали высо-кий уровень расходов при СД2 [13].…”